Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY: NVO )

87.65 +0.28 (+0.32%)
Official Closing Price Updated: 7:00 PM EST, Dec 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
68 69 Next >
$100 Invested In This Stock 10 Years Ago Would Be Worth $600 Today
Via Benzinga
The 3 Best Healthcare Stocks to Buy in July 2024
Consistent breakthroughs, improved products and relatively consistent growth make these the best healthcare stocks to buy. 
Via InvestorPlace
S&P 500, Nasdaq 100 Climb To Record Highs As Data Fosters Rate Cut Optimism Ahead Of Fed Minutes; Gold, Bonds Rally: What's Driving Markets Wednesday?
The S&P 500 and Nasdaq 100 indices surged to new all-time highs on Thursday, as investors heightened their expectations for rate cuts following June’s sharply lower-than-expected services sector... 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Using Obesity Drugs? Potential Vision Loss Disorder Linked To Novo Nordisk's Ozempic And Wegovy, Study Finds
New study suggests a potential link between Novo Nordisk's GLP-1 drugs, Ozempic and Wegovy, and NAION, a condition that can cause vision loss. Researchers urge further analysis and awareness for... 
Via Benzinga
Why Novo Nordisk Stock Is Slipping Today
President Biden and Sen. Bernie Sanders warned the drugmaker against "ripping off the American people." 
Via The Motley Fool
Beyond The Numbers: 8 Analysts Discuss Novo Nordisk Stock
Via Benzinga
Novo Nordisk Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
Novo Nordisk, Eli Lilly Tumble After Study Suggests Weight-Loss Drugs Can Lead To Blindness
The study comes out of a Harvard teaching hospital based in Boston. 
Via Investor's Business Daily
The 7 Best Stocks to Buy in July 2024
Investors looking to for the best stocks to buy as we enter the year's second half and add some winners should consider these securities. 
Via InvestorPlace
Altimmune Stock: Is Its GLP-1 Drug the Next Ozempic Killer?
Clinical-state biopharmaceutical company Altimmune Inc. (NASDAQ: ALT) focuses on developing peptide-based therapeutics for obesity and chronic liver diseases 
Via MarketBeat
Exposures Product Safety
Eli Lilly Snags Long-Awaited Alzheimer's Drug Approval, Rivaling Biogen, Eisai
The company is on deck to rival Biogen and Eisai's Leqembi. 
Via Investor's Business Daily
Joe Biden Suggests Novo Nordisk, Eli Lilly To Lower Prices For Its Popular Obesity Drugs
American leaders push for lower drug prices, highlighting recent legislation and widespread support for affordable medications. The Inflation Reduction Act caps insulin costs and Medicare now... 
Via Benzinga
Topics Economy
Exposures Interest Rates
Should you consider NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) for quality investing?
Why NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) qualifies as a quality stock. 
Via Chartmill
Novo, Lilly Dive After Biden Slams Duo For 'Unconscionably High' Drug Prices
The duo make weight-loss and diabetes drugs that sell for more than $1,000 a month before insurance kicks in. 
Via Investor's Business Daily
Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes
Pharmaceutical giant Pfizer Inc. (NYSE: PFE) has been trying to enter the weight-loss treatment trend dominated by GLP-1 drug makers like Ozempic and Wegovy 
Via MarketBeat
3 Under-the-Radar Biotech Stocks With Blockbuster Potential
Are you looking to boost your portfolio with the best under-the-radar biotech stocks? Here are the top three. 
Via InvestorPlace
Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Global pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) has made headlines with its leading GLP-1 weight loss drugs, Mounjaro and Zepbound. 
Via MarketBeat
Exposures Product Safety
3 Breakout Biotech Stocks on Track to Double by 2032
The tech sector has been at the forefront of the market rally in 2024. Consider these breakout biotech stocks as a great way to diversify. 
Via InvestorPlace
Week In Review: Fosun Pharma Plans $690 Million Deal To Privatize Henlius, Its Biologics Subsidiary
Shanghai Henlius Biotech agreed to be a wholly owned subsidiary of Fosun in a $690 million deal that values the company at $1.7 billion. Meanwhile, Suzhou Ascentage Pharma filed to list in the US to... 
Via Talk Markets
Surprise! Novo Nordisk's Wegovy Just Achieved Another Milestone. Here's What You Need to Know.
Wegovy was just approved in China. 
Via The Motley Fool
If These 3 Words Are True, Altimmune's Weight Loss Candidate Could Beat Novo Nordisk's Wegovy
The market for weight loss medicines keeps getting hotter and hotter. 
Via The Motley Fool
This Is Massive News for Eli Lilly Investors
A panel of advisors to the Food and Drug Administration (FDA) recently recommended Eli Lilly's Alzheimer's candidate. 
Via The Motley Fool
Eli Lilly Is Teaming Up With OpenAI. Here Are 3 Things Smart Investors Should Know.
Eli Lilly is the latest major pharmaceutical company to bring artificial intelligence (AI) to the healthcare sector. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Stock Market Rally Powers To Fresh Highs; Carnival, Micron, Nike In Focus: Weekly Review
Software, small caps and megacaps were standouts. 
Via Investor's Business Daily
The Top 3 Weight Loss Drug Stocks to Buy for Huge Gains
Consider buying shares in these pharma companies, each of which is a leader in the weight loss drug sector. 
Via InvestorPlace
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030
These healthcare stocks have clear paths to growth over the next few years. 
Via The Motley Fool
Novo Nordisk Buys 2seventy's Hemophilia A Program, Divestiture Supports Exclusive Focus On Abecma
2seventy Bio finalized an asset purchase agreement with Novo Nordisk involving the Hemophilia A program and in vivo gene editing technology. The 2seventy bio team will join Novo Nordisk, focusing on... 
Via Benzinga
Volkswagen Puts Our Rivian Bet In The Black: The Pros And Cons Of Trading Options Versus Stocks
Novo Nordisk, Carvana, And Now Rivian 
Via Benzinga
Novo Nordisk To Restrict Initial Wegovy Sales In China Amid High Demand
Novo Nordisk will limit initial sales of Wegovy in China to manage global supply and address the rising obesity rates in the world's most populous country. The competitive landscape and regulatory... 
Via Benzinga
Hims & Hers Health Stock Is Sliding Thursday: What's Going On?
Hunterbrook releases a bearish report alleging that Hims & Hers sells knockoff GLP-1 weight loss drugs and relies on a single supplier with previously unreported ties to fraud and bankruptcy. 
Via Benzinga
Topics Fraud Supply Chain
Exposures Legal Supply Chain
< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
68 69 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.